Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (141-150 of 177) with videos related to

Pageof 18
Sort By:
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Drugs|February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Lancet (London, England)|December 20, 2024
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T Rubin, Jessica R Allegretti, Julián Panés, et al.
Zeitschrift Fur Gastroenterologie|August 7, 2024
Andreas Sturm, Raja Atreya, Dominik Bettenworth, et al.
Gastroenterology|September 2, 2023
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin-Biroulet, Jessica R Allegretti, David T Rubin, et al.
The American Journal of Gastroenterology|May 1, 2026
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension StudyGary R Lichtenstein, Jessica R Allegretti, David T Rubin, et al.
Journal of Crohn'S & Colitis|August 31, 2023
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ExtensionSilvio Danese, Remo Panaccione, Maria T Abreu, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meetingTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Pageof 18

Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Drugs|February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Lancet (London, England)|December 20, 2024
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T Rubin, Jessica R Allegretti, Julián Panés, et al.
Zeitschrift Fur Gastroenterologie|August 7, 2024
Andreas Sturm, Raja Atreya, Dominik Bettenworth, et al.
Gastroenterology|September 2, 2023
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction StudyLaurent Peyrin-Biroulet, Jessica R Allegretti, David T Rubin, et al.
The American Journal of Gastroenterology|May 1, 2026
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension StudyGary R Lichtenstein, Jessica R Allegretti, David T Rubin, et al.
Journal of Crohn'S & Colitis|August 31, 2023
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ExtensionSilvio Danese, Remo Panaccione, Maria T Abreu, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meetingTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Pageof 18